Bio-Rad wins appeal in 10x Genomics patent infringement ruling

By The Science Advisory Board staff writers

Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed a patent that had been exclusively licensed to Bio-Rad by the University of Chicago.

The Court of Appeals also upheld the lower court's finding for $23.9 million in monetary damages, awarding Bio-Rad a 15% royalty on past and future sales, and a permanent injunction against 10x's Single Cell 3' gene expression products, Single Cell assay for transposase accessible chromatin (ATAC)-seq products, and Single Cell V(D)J products that were found to infringe U.S. Patent 8,889,083, Bio-Rad said.

However, the Court of Appeals also withdrew the District Court's injunction with respect to 10x's Linked-Read and copy number variation (CNV) product lines and reversed the District Court's decision on infringement of two other patents asserted by Bio-Rad. The company said that it does not believe these aspects of the decision will have a material impact on the overall result and is evaluating its options for further review.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking